RT Journal Article
SR Electronic
T1 HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL PROGNOSTIC FACTORS IN HIGH-GRADE NON-ENDOMETRIOID CARCINOMAS OF THE ENDOMETRIUM (HG-NECs). IS IT POSSIBLE TO IDENTIFY SUB-GROUPS AT INCREASED RISK?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.09.21256904
DO 10.1101/2021.05.09.21256904
A1 Vellone, Valerio Gaetano
A1 Paudice, Michele
A1 Biatta, Chiara Maria
A1 Scaglione, Giulia
A1 Barra, Fabio
A1 Ferrero, Simone
A1 Greppi, Marco
A1 Paleari, Laura
A1 Marcenaro, Emanuela
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.05.09.21256904.abstract
AB Endometrial cancer is an emerging disease with an increase in prevalence of aggressive histotypes in recent years. In the present study potential histopathological and immunohistochemical prognostic markers are investigatedConsecutive cases of high grade non-endometrioid carcinoma (HG-NEC) of the endometrium were considered. Each surgical specimen has been routinely processed, the most representative block has been selected for immunohistochemistry and tested for ER, PR, ki67, p53, E-cadherin, β-catenin, Bcl-2 and cyclin D1. For each immunomarker the percentage of positive tumor cells were evaluated (%) and dichotomized as low and high according to the distribution in the study population. Follow-up was collected for disease-free survival (DFS) and overall survival (OS).33 cases were eligible: 19 resulted FIGO I-II, 14 resulted FIGO III-IV. 12 patients suffered a recurrent disease (mean follow-up 24.6 months); 8 patients died of the disease (mean follow-up 26.6 months).Women with recurrent disease demonstrated a significant higher bcl2% (35.84±30.96% vs 8.09±11.56% p=0.0032) while DOD patients had higher ki67% (75±13.09% vs 58.6±19.97% p=0.033) and bcl2% of border significance (34.37±34.99% vs 13±17.97% p=0.078).As expected FIGO III-IV had a worse DFS (HR=3.34; 95%CI:1.1-10.99; p=0.034) and OS (HR=5.19; 95%CI: 1.27-21.14 p= 0.0217). Bcl2-high patients (bcl2>10%) demonstrated a significant worse DFS (HR=9.11; 95%CI: 2.6-32.4; p=0.0006) and OS (HR=7.63; 95%CI:1.7-34; p=0.0084); also PR low patients (PR≤10%) had a significant worse DFS (HR=3.74; 95%CI:1.2-11.9; p=0,02).HG-NEC represent an heterogeneous group of endometrial aggressive neoplasms with a worrisome prognosis often at an advanced stage at presentation. Bcl2 and PR may represent promising markers to identify a sub-group of patients having an even worse prognosis requiring a careful and close follow-up.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRetrospective StudyFunding StatementFunding: the current work was granted by University of Genoa Research Funds (FRA)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Liguria Regional Ethic Committee (Prot. Pubb.HG-NECs_Vellone2021)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailability of data and material (data transparency): the presented dated are available to asking scholars